Nivolumab: tested in a combination
680 studies: another drug in the study is under test too. Page 7 of 7. Open to participants first (135), then studies with results posted, then the rest; newest registration first within each.
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1Report a problem
- Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCLCompletedNCT03259529Phase 1/2Report a problem
- A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerCompletedNCT03245892Phase 1Report a problem
- Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStatus unknownNCT03241186Phase 2Report a problem
- An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2Report a problem
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerActive, not recruitingNCT03223155Phase 1Report a problem
- Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaWithdrawnNCT03220009Phase 2Report a problem
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell CarcinomaStatus unknownNCT03219775Phase 2Report a problem
- Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)Status unknownNCT03219671Phase 2Report a problem
- Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver CancerTerminatedNCT03203304Phase 1Report a problem
- Nivolumab Combined With Daratumumab With or Without Low-dose CyclophosphamideCompletedNCT03184194Phase 2Report a problem
- Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)Status unknownNCT03177239Phase 2Report a problem
- Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaActive, not recruitingNCT03172754Phase 1/2Report a problem
- Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerCompletedNCT03162731Early Phase 1Report a problem
- Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWithdrawnNCT03149159Phase 2Report a problem
- A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver CancerCompletedNCT03143270Early Phase 1Report a problem
- SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsWithdrawnNCT03126461Phase 2Report a problem
- Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabCompletedNCT03126331Phase 2Report a problem
- A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2Report a problem
- Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerActive, not recruitingNCT03104439Phase 2Report a problem
- Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaActive, not recruitingNCT03097939Phase 2Report a problem
- Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerTerminatedNCT03091491Phase 2Report a problem
- BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerCompletedNCT03083691Phase 2Report a problem
- Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCCCompletedNCT03075423Phase 2Report a problem
- Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureActive, not recruitingNCT03061539Phase 2Report a problem
- Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2Report a problem
- A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWithdrawnNCT03048136Phase 3Report a problem
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2Report a problem
- ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaCompletedNCT03003637Phase 1/2Report a problem
- A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ CancerCompletedNCT02999295Phase 1/2Report a problem
- A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaStatus unknownNCT02982486Phase 2Report a problem
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2Report a problem
- Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2Report a problem
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2Report a problem
- Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02950038Phase 2Report a problem
- Study to Nivolumab Following Preoperative ChemoradiotherapyStatus unknownNCT02948348Phase 1/2Report a problem
- Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsCompletedNCT02946671Phase 1Report a problem
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2Report a problem
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaActive, not recruitingNCT02940301Phase 2Report a problem
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersCompletedNCT02923934Phase 2Report a problem
- Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell CarcinomaCompletedNCT02917772Phase 2Report a problem
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2Report a problem
- Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2Report a problem
- Nivolumab in Relapsed Pediatric Solid TumorsStatus unknownNCT02901145Phase 1/2Report a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02880020Phase 2Report a problem
- Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsCompletedNCT02866383Phase 2Report a problem
- Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantTerminatedNCT02846376Phase 1Report a problem
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2Report a problem
- Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasCompletedNCT02829931Phase 1Report a problem
- Study of ONO-4538 in Gastric CancerCompletedNCT02746796Phase 2/3Report a problem
- Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneWithdrawnNCT02736123Phase 1/2Report a problem
- Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsCompletedNCT02716272Phase 2Report a problem
- Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerActive, not recruitingNCT02696993Phase 1/2Report a problem
- Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent GlioblastomaTerminatedNCT02648633Phase 1Report a problem
- Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2Report a problem
- Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2Report a problem
- Nivo/Ipi Combination Therapy in Symptomatic Brain MetastasesTerminatedNCT02621515Phase 2Report a problem
- Combination of Interferon-gamma and Nivolumab for Advanced Solid TumorsCompletedNCT02614456Phase 1Report a problem
- Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2Report a problem
- Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDCompletedNCT02523313Phase 2Report a problem
- Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) PatientsActive, not recruitingNCT02499367Phase 2Report a problem
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2Report a problem
- A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisStatus unknownNCT02460068Phase 3Report a problem
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasActive, not recruitingNCT02451982Phase 2Report a problem
- Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma PatientsActive, not recruitingNCT02437279Phase 1Report a problem
- Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT02393794Phase 1/2Report a problem
- Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1Report a problem
- Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesActive, not recruitingNCT02374242Phase 2Report a problem
- Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibWithdrawnNCT02357732Phase 1Report a problem
- Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1Report a problem
- Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1Report a problem
- Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs ObservationCompletedNCT02196961Phase 2Report a problem
- Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1Report a problem
- Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT01940809Phase 1Report a problem
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT01896999Phase 1/2Report a problem
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1Report a problem
- Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsCompletedNCT01629758Phase 1Report a problem
- Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedNCT01176474Phase 1Report a problem
- A Study of MDX-1106 to Treat Patients With Hepatitis C InfectionCompletedNCT00703469Phase 1Report a problem